Precision Neuromodulation Decreased Brain Atrophy and Increased Connectivity in Key Brain Network in Alzheimer’s Patients
![](https://sinapticatx.com/wp-content/uploads/2024/07/Alzheimers-Research-Therapy-1.png)
Study by Sinaptica scientific co-founders published in Alzheimer’s Research & Therapy Imaging analysis revealed personalized rTMS-EEG preserved structural integrity, enhanced functional connectivity, and slowed atrophy in areas of the Default Mode Network, the primary memory network impacted by Alzheimer’s that is targeted by the therapy Findings support the company’s Phase 2 data in Mild/Moderate Alzheimer’s […]
Alzheimer’s: Approaching a Cure
![](https://sinapticatx.com/wp-content/uploads/2024/06/newsweek-article-sinaptica.png)
This Phase 2 trial showed 80 percent+ slowing of Alzheimer’s progression on gold standard cognitive and functional endpoints using non-invasive neuromodulation, leading to Sinaptica’s founding. I’ve never encountered placebo–controlled efficacy data as strong.KEN MARIASH | CEO, SINAPTICA Prevalence and Economic ImpactAlzheimer’s slow impairment of memory and cognitive functions continues to divide the wider scientific community, […]
Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc.
![](https://sinapticatx.com/wp-content/uploads/2024/06/06-07-24-Sinaptica-Nextim-logos-for-press-release-1.png)
Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces that it has successfully negotiated and signed a Letter of Intent (LOI) to exclusively collaborate with Sinaptica Therapeutics, Inc. (“Sinaptica”) to develop, manufacture and supply Sinaptica’s patented precision neuromodulation system custom-based upon the Nexstim NBS 6 system with its advanced TMS-EEG and precision neuronavigation capabilities, in the field […]
Sinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s Moonshot
![](https://sinapticatx.com/wp-content/uploads/2024/05/startup-health-thumbnail-1.jpg)
Moonshot supported by Gates Ventures and Alzheimer’s Drug Discovery Foundation (ADDF)to accelerate innovation around Alzheimer’s Sinaptica is one of 14 companies initially selected that are advancing innovative solutions for Alzheimer’s to commercialization and scalability Collaboration will support the company’s Phase 3 clinical development plans based on unprecedented Phase 2 data in Alzheimer’s showing >80% disease […]
Sinaptica Completes Scientific Advisory Board with Final Expert Appointment as Company Advances to Pivotal Trial in Alzheimer’s
![](https://sinapticatx.com/wp-content/uploads/2024/02/sinaptica-blog-post.jpg)
Giovanni Frisoni, MD joins SAB comprised of prominent global Alzheimer’s, neuromodulation and neuroscience experts including Jeffrey Cummings MD, ScD(HC); Ana Pereira MD; Simone Rossi MD, PhD; Casey Lynch, MS SAB will help guide the company’s Phase 3 clinical development plans based on unprecedented Phase 2 data in Alzheimer’s showing >80% disease slowing on cognitive & […]
Shaping the Future of Alzheimer’s Care: Interview with Sinaptica CEO Ken Mariash
![](https://sinapticatx.com/wp-content/uploads/2024/01/Group-129.png)
Researchers have been looking for a cure for Alzheimer’s disease for decades, with little success. Traditionally, the arsenal we’ve been using is largely reliant upon drugs. But could a device, not a pharmaceutical, be the key to Alzheimer’s treatment? This is a possibility that Ken Mariash and his team are solving for at Sinaptica. Ken […]
Alzheimer’s Disease: Can Machine Learning Fix a Broken Brain Network?
![](https://sinapticatx.com/wp-content/uploads/2023/11/medtech-strategist-logo.png)
Sinaptica began its commercial journey only recently, although its deep scientific underpinnings have already gotten it through a positive Phase II trial, which dramatically showed the benefit of a noninvasive neuromodulation therapy designed to achieve a network effect that slows disease progression in patients with mild to moderate Alzheimer’s. The pathophysiology of Alzheimer’s disease is […]
Sinaptica Therapeutics: MedTech Upstart Takes on Alzheimer’s with Radical New Approach
![](https://sinapticatx.com/wp-content/uploads/2023/11/medtech-cover-806x1024.png)
Precision Neuromodulation of the Default Mode Network slows disease progression by an unprecedented 80%+ in landmark Phase 2 clinical study. Researchers have spent decades and billions trying to develop an effective treatment for Alzheimer’s disease, the most feared disease, ahead of cancer, stroke, and heart disease combined—according to a survey by the Milken Institute. Pharmaceutical […]
It’s not just about plaques: rTMS also reduces cognitive and functional decline in Alzheimer’s
![](https://sinapticatx.com/wp-content/uploads/2023/07/bioworld-medtech.png)
The growing number of drugs gaining U.S. FDA approval for Alzheimer’s disease has kept their ability to reduce amyloid beta and tau proteins in the news, but the degenerative disease is not simply a matter of tangles and deposits. A loss of synaptic plasticity and disrupted neural networks underlie the signature impairment of memory and […]
Sinaptica Appoints Ken Mariash CEO
![](https://sinapticatx.com/wp-content/uploads/2023/07/Group-119.png)
Company accelerates after unprecedented positive Phase 2 data in Alzheimer’s, showing >80% disease slowing on cognitive & functional endpoints CAMBRIDGE, Mass.-– Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer. […]